Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK002 in Indolent Systemic Mastocytosis
NCT02808793Phase 1Completed
- Sponsor
- Allakos Inc.
- Start
- Jun 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lirentelimab in indolent systemic mastocytosis (ISM), sponsored by Allakos Inc. Primary endpoint: Safety and Tolerability at Day 85. Started Jun 2016; status: completed.
02
Drugs
lirentelimab
03
Conditions
indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on NCT02808793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808793.